45 related articles for article (PubMed ID: 35279611)
1. Structure-based discovery of receptor tyrosine kinase AXL degraders with excellent anti-tumor activity by selectively degrading AXL and inducing methuosis.
Shi W; Feng Z; Chi F; Zhou J; Qiu Q; Jiang Y; Chen S; Zhong Y; Jia H; Huang W; Qian H
Eur J Med Chem; 2022 Apr; 234():114253. PubMed ID: 35279611
[TBL] [Abstract][Full Text] [Related]
2. Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells.
He R; Song Z; Bai Y; He S; Huang J; Wang Y; Zhou F; Huang W; Guo J; Wang Z; Tu ZC; Ren X; Zhang Z; Xu J; Ding K
J Med Chem; 2023 Feb; 66(3):1873-1891. PubMed ID: 36695404
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 10
Zhan Z; Ji Y; Su H; Fang C; Peng X; Liu Q; Dai Y; Lin D; Xu Y; Ai J; Duan W
J Med Chem; 2023 Jan; 66(1):220-234. PubMed ID: 36524812
[TBL] [Abstract][Full Text] [Related]
4. Quinolone antibiotic derivatives as new selective Axl kinase inhibitors.
Tan L; Zhang Z; Gao D; Chan S; Luo J; Tu ZC; Zhang ZM; Ding K; Ren X; Lu X
Eur J Med Chem; 2019 Mar; 166():318-327. PubMed ID: 30731400
[TBL] [Abstract][Full Text] [Related]
5. Discovery of a 1,6-naphthyridin-4-one-based AXL inhibitor with improved pharmacokinetics and enhanced in vivo antitumor efficacy.
Lan Y; Peng X; Ji Y; Su Y; Duan W; Ai J; Zhang H
Eur J Med Chem; 2024 Feb; 265():116045. PubMed ID: 38128234
[TBL] [Abstract][Full Text] [Related]
6. The JNK signaling pathway plays a key role in methuosis (non-apoptotic cell death) induced by MOMIPP in glioblastoma.
Li Z; Mbah NE; Overmeyer JH; Sarver JG; George S; Trabbic CJ; Erhardt PW; Maltese WA
BMC Cancer; 2019 Jan; 19(1):77. PubMed ID: 30651087
[TBL] [Abstract][Full Text] [Related]
7. Discovery of 3-Aminopyrazole Derivatives as New Potent and Orally Bioavailable AXL Inhibitors.
Chan S; Zhang Y; Wang J; Yu Q; Peng X; Zou J; Zhou L; Tan L; Duan Y; Zhou Y; Hur H; Ai J; Wang Z; Ren X; Zhang Z; Ding K
J Med Chem; 2022 Nov; 65(22):15374-15390. PubMed ID: 36358010
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic activity of DCC-2036, a novel tyrosine kinase inhibitor, against triple-negative breast cancer patient-derived xenografts by targeting AXL/MET.
Shen Y; Zhang W; Liu J; He J; Cao R; Chen X; Peng X; Xu H; Zhao Q; Zhong J; Ding W; Lei X; Jiang Y; Zu X
Int J Cancer; 2019 Feb; 144(3):651-664. PubMed ID: 30289981
[TBL] [Abstract][Full Text] [Related]
9. Structure-based drug discovery of novel fused-pyrazolone carboxamide derivatives as potent and selective AXL inhibitors.
Fang F; Dai Y; Wang H; Ji Y; Liang X; Peng X; Li J; Zhao Y; Li C; Wang D; Li Y; Zhang D; Zhang D; Geng M; Liu H; Ai J; Zhou Y
Acta Pharm Sin B; 2023 Dec; 13(12):4918-4933. PubMed ID: 38045061
[TBL] [Abstract][Full Text] [Related]
10. Structure-based discovery of potent inhibitors of Axl: design, synthesis, and biological evaluation.
Wu S; Liao M; Li M; Sun M; Xi N; Zeng Y
RSC Med Chem; 2022 Oct; 13(10):1246-1264. PubMed ID: 36325401
[TBL] [Abstract][Full Text] [Related]
11. Discovery of Potent and Selective Phosphatidylinositol 3-Phosphate 5-Kinase (PIKfyve) Inhibitors as Methuosis Inducers.
Chen Y; Liu S; Wei Y; Wei H; Yuan X; Xiong B; Tang M; Yang T; Yang Z; Ye H; Yang J; Chen L
J Med Chem; 2024 Jan; 67(1):165-179. PubMed ID: 38117948
[TBL] [Abstract][Full Text] [Related]
12. Progress in the discovery and development of small molecule methuosis inducers.
Ye T; Shan P; Zhang H
RSC Med Chem; 2023 Aug; 14(8):1400-1409. PubMed ID: 37593581
[TBL] [Abstract][Full Text] [Related]
13. Discovery a series of quinazolin derivatives as potent AXL inhibitors.
Zhang LL; Wu J; Li DD; Ji XJ; Ma CY; Xu D
Eur J Med Chem; 2022 Jul; 237():114316. PubMed ID: 35483321
[No Abstract] [Full Text] [Related]
14. Differential Induction of Cytoplasmic Vacuolization and Methuosis by Novel 2-Indolyl-Substituted Pyridinylpropenones.
Trabbic CJ; Dietsch HM; Alexander EM; Nagy PI; Robinson MW; Overmeyer JH; Maltese WA; Erhardt PW
ACS Med Chem Lett; 2014 Jan; 5(1):73-77. PubMed ID: 24527179
[TBL] [Abstract][Full Text] [Related]
15. Tubeimoside-2 Triggers Methuosis in Hepatocarcinoma Cells through the MKK4-p38α Axis.
Gan Y; Wang C; Chen Y; Hua L; Fang H; Li S; Chai S; Xu Y; Zhang J; Gu Y
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111582
[TBL] [Abstract][Full Text] [Related]
16. Author Correction: The effect of inhibition of receptor tyrosine kinase AXL on DNA damage response in ovarian cancer.
Yeo XH; Sundararajan V; Wu Z; Phua ZJC; Ho YY; Peh KLE; Chiu YC; Tan TZ; Kappei D; Ho YS; Tan DSP; Tam WL; Huang RY
Commun Biol; 2023 Jul; 6(1):759. PubMed ID: 37474650
[No Abstract] [Full Text] [Related]
17. Degradation of Protein Kinases: Ternary Complex, Cooperativity, and Selectivity.
Grigglestone CE; Yeung KS
ACS Med Chem Lett; 2021 Nov; 12(11):1629-1632. PubMed ID: 34795847
[TBL] [Abstract][Full Text] [Related]
18. Methuosis Contributes to Jaspine-B-Induced Cell Death.
Bielsa N; Casasampere M; Abad JL; Enrich C; Delgado A; Fabriàs G; Lizcano JM; Casas J
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35806262
[TBL] [Abstract][Full Text] [Related]
19. V-ATPase V0 subunit activation mediates maduramicin-induced methuosis through blocking endolysosomal trafficking in vitro and in vivo.
Zheng Y; Xiao J; Wang J; Dong B; Guo D; Ji H; Sun H; Peng L; Jiang S; Gao X
Food Chem Toxicol; 2023 Aug; 178():113922. PubMed ID: 37394175
[TBL] [Abstract][Full Text] [Related]
20. Discovery of Pyrimidinediamine Derivatives as Potent Methuosis Inducers for the Treatment of Triple-Negative Breast Cancer.
He J; Wang L; Mi D; Guan T; Liu W; He P; Gu H; Li Y; Peng Y; Jia AQ; Chen C; Chen Y
J Med Chem; 2023 Jun; 66(11):7421-7437. PubMed ID: 37212861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
